Micafungin - The newest echinocandin

Zelalem Temesgen, Jason Barreto, Sandro Vento

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is generally well tolerated with few significant adverse effects.

Original languageEnglish (US)
Pages (from-to)469-478
Number of pages10
JournalDrugs of Today
Volume45
Issue number6
DOIs
StatePublished - Jun 1 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Micafungin - The newest echinocandin'. Together they form a unique fingerprint.

Cite this